Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Masitinib for primary and relapse-free secondary progressive multiple sclerosis – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Masitinib is intended to be used as first line therapy for the treatment of primary progressive or relapse-free secondary progressive multiple sclerosis. If licensed, masitinib will offer a novel, oral treatment option for this patient group for whom no licensed therapies are currently available. Masitinib is a highly selective, orally administered tyrosine kinase inhibitor that targets the c-Kit, Lyn and Fyn signalling pathways. Masitinib does not currently have Marketing Authorisation in the EU for any indication.
Multiple sclerosis is a chronic immune-mediated condition of the central nervous system characterised by demyelination and axonal degeneration. Around 107,000 people in the UK currently have multiple sclerosis and there are approximately 6,000 new diagnoses each year. Multiple sclerosis is usually diagnosed between the ages of 20 and 50 years, and is the most common cause of non-traumatic neurological disability in young adults. It causes high levels of disability and impaired quality of life for long periods and is associated with a high rate of unemployment in early adulthood.
The aim of treatment is to relieve symptoms, prevent or delay disability arising from disease progression and promote tissue repair to treat established progression. There are currently no disease-modifying therapies available for primary progressive multiple sclerosis, and options of only limited efficacy for secondary progressive disease. Masitinib is currently in a phase III clinical trial comparing its effect on the Multiple Sclerosis Functional Composite against treatment with placebo. Indexing Status Subject indexing assigned by CRD MeSH Chronic Disease; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Recurrence; Thiazoles Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000387 Date abstract record published 04/03/2016 |